To determine whether these tumor types may be susceptible to disruption of the CD47-SIRPα axis using this strategy, gene expression levels of CD47-SIRPα and CD163 (a marker of monocyte/macrophage infiltration) were assessed in bulk tumor samples using data from TCGA. This evidence concerns the gene SIRPA and neoplasm.